에 대한 최신 뉴스 StoneCo (NASDAQ:STNE) 주식

StoneCo

StoneCo Ltd is a provider of financial technology solutions. It serves MSMBs solutions, at fair prices, and provides the customer experience to help them manage their businesses and sell more. Its Stone Business Model combines end-to-end, cloud-based technology platforms; differentiated hyper-local and integrated distribution approaches; and white-glove, on-demand customer service. It has two segments Financial Services segment, which includes payments solutions, digital banking, credit, insurance solutions as well as the registry business. In the Software segment solution includes POS/ERP, TEF and QR Code gateways, reconciliation, CRM, OMS, e-commerce platform, engagement tool, ads solution, and marketplace hub. It generates the majority of its revenue from the Financial Services segment.

Lucid EV. Photo by Around the World Photos on Shutterstock

Equities

Mid Cap

News

Movers

Tech

ARQT

CELH

CPRX

DGNX

GLNG

LCID

SBSW

STNE

지난 일주일 동안 가장 실적이 좋았던 중형주 10개 종목은 다음과 같다. 디지넥스, 넥스트데케이드, 셀시우스, 시그넷 주얼러스, 뉴 포트리스, 밀로즈, 아커티스, 루시드, 캐털리스트, 스톤코

셀시우스·루시드·시그넷 등 지난주 급등한 중형주 10종목 (3월 17일~21일)

Earnings

Pre-Market Outlook

Markets

Trading Ideas

FIVE

수요일 아침 (현지 시간 기준) 미국 주식 선물이 상승세를 보인 가운데, 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 월스트리트는 시그넷 주얼러스(NYSE:SIG)가 분기 실적을 주당 6.25달러, 매출을 23억 3천만 달러로 발표할 것으로 예상하고 있다. Benzinga Pro의 데이터에 따르면, 시그넷의 주식은 시간외 거래에서 0.3% 상승한 48.42달러에 거래되었다.

수요일 주목해야 할 주식: 윌리엄스-소노마, 헬스에퀴티, 시그넷, 스톤코 및 파이브 빌로우

Market,Sentiment,,Fear,And,Greed,Index,,Emotional,On,Stock,Market

BIDU

CWCO

GETY

SAIC

CNN 머니 공포·탐욕 지수는 전체 시장 정서에서 약간의 개선을 보여주었지만, 월요일에도 여전히 &#34;극단적 공포&#34; 영역에 머물렀다.미국 주식은 월요일(17일)에 상승세를 보였으며, 다우존스 지수가 거래 중에 350포인트 이상 급등했다. 주요 지수 3개 모두 연속으로 상승했다.

긍정적 경제지표로 다우 지수 350p 상승: 투자자 불안 완화, 탐욕 지수는 &#39;극단적 공포&#39; 영역

StoneCo Ltd

MercadoLibre Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) shares are rising in extended trading on Wednesday after the company reported better-than-expected results <a href="https://www.benzinga.com/pressreleases/25/05/g45267551/mercado-libre-builds-on-2024-momentum-with-strong-q1-2025-results-reporting-5-9-billion-revenue-an">for the first quarter</a>.
<ul>
<li>Q1 Revenue: $5.93 billion, versus <a href="http://benzinga.com/quote/meli/estimates">estimates</a> of $5.51 billion</li>
</ul>
<ul>
<li>Q1 EPS: $9.74, versus estimates of $8.03</li>
</ul>
Total revenue increased 37% on a year-over-year basis, boosted by continued strategic investments. Commerce revenue climbed 32% year-over-year, Financial revenue increased 37% and Fintech revenue from Mercado Pago jumped 43%. 
The Latin America e-commerce and fintech platform company said brand preference reached all-time highs in key markets during the quarter, including Brazil, Mexico, Argentina and Chile. 
&#8220;Mercado Libre started 2025 with exceptional momentum, driven by strong operational performance across both commerce and fintech,&#8221; said Martin de los Santos, CFO of MercadoLibre.
&#8220;This quarter highlights our continued commitment to sustainable, profitable growth as we capture the many opportunities ahead. We remain a key force in accelerating the shift from traditional retail to e-commerce, supported by ongoing investments aimed at delivering a seamless user experience.&#8221;
MELI Price Action: <a href="http://benzinga.com/quote/meli">MercadoLibre shares</a> were up 1.48% in Wednesday&#8217;s after-hours session, trading at $2,262.09 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/25/05/45183831/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-63">Benzinga&#8217;s &#8216;Stock Whisper&#8217; Index: 5 Stocks Investors Secretly Monitor But Don&#8217;t Talk About Yet</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/Octavio_Hoyos">Octavio Hoyos</a>/Shutterstock.

Fintech news covering the emerging Financial Technology services sector

Fintech

Global

MELI

MercadoLibre Stock Surges On Q1 Earnings Beat: 'Exceptional Momentum'

Bank Bradesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBDO#NYSE">BBDO</a>) reported quarterly earnings of $0.09 per share. This is a 21.43 percent increase over earnings of $0.07 per share from the same period last year. The company reported $3.82 billion in sales this quarter. This is a 4.63 percent increase over sales of $3.65 billion the same period last year.

BBDO

Bank Bradesco Q1 EPS $0.09 Up From $0.07 YoY, Sales $3.82B Up From $3.65B YoY

Pizza Pizza Royalty (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PZA#TSX">PZA</a>) reported quarterly earnings of $0.23 per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported $9.73 million in sales this quarter. This is a 1.85 percent increase over sales of $9.55 million the same period last year.

TSX:PZA

Pizza Pizza Royalty Q1 Adj. EPS $0.23, Inline, Sales $9.73M Up From $9.55M YoY

Offerpad Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPAD#NYSE">OPAD</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $2.54, a high estimate of $4.50, and a low estimate of $1.00. This current average represents a 28.85% decrease from the previous average price target of $3.57. 
<img src="https://www.benzinga.com/files/images/story/2025/1746655276_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Offerpad Solutions by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Tomasello</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$1.00</td>
<td>$2.25</td>
</tr>
<tr>
<td>Michael Ng</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.00</td>
<td>$2.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$4.50</td>
<td>$4.50</td>
</tr>
<tr>
<td>Ryan Tomasello</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$2.25</td>
<td>$3.15</td>
</tr>
<tr>
<td>Michael Ng</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$2.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$4.50</td>
<td>$4.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Offerpad Solutions. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Offerpad Solutions compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Offerpad Solutions's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Offerpad Solutions's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OPAD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Offerpad Solutions analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Offerpad Solutions</h2>
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services including mortgage, listing, renovation and buyer representation services.
<h3>Offerpad Solutions: Delving into Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Offerpad Solutions's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -27.52% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -9.94%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Offerpad Solutions's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -30.84%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Offerpad Solutions's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -5.32%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Offerpad Solutions's debt-to-equity ratio stands notably higher than the industry average, reaching 5.0. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

OPAD

What Analysts Are Saying About Offerpad Solutions Stock

Across the recent three months, 7 analysts have shared their insights on Expeditors International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXPD#NYSE">EXPD</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $113.29, a high estimate of $128.00, and a low estimate of $105.00. Highlighting a 3.85% decrease, the current average has fallen from the previous average price target of $117.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1746655268_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Expeditors International. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas Wadewitz</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$117.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Brandon Oglenski</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$105.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Lucas Servera</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$105.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Lucas Servera</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Hold</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Bascome Majors</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Brian Ossenbeck</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$108.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Thomas Wadewitz</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$128.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Expeditors International. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Expeditors International compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Expeditors International's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EXPD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Expeditors International analyst ratings.</a>
<h2>All You Need to Know About Expeditors International</h2>
Based in the US, Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. Its offers freight consolidation and forwarding, customs brokerage, warehousing and distribution, purchase order management, vendor consolidation, and numerous other value-added logistics services. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. Expeditors derives around 35% of consolidated gross revenue from airfreight, 30% from ocean freight, and 36% from customs brokerage and other services.
<h3>A Deep Dive into Expeditors International's Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Expeditors International's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 29.72%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Net Margin: Expeditors International's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.98% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 10.3%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Expeditors International's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.75% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Expeditors International's debt-to-equity ratio is below the industry average. With a ratio of 0.26, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXPD

What 7 Analyst Ratings Have To Say About Expeditors International

Bumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) sees Q2 sales of $235.000 million-$243.000 million vs $243.71 million analyst estimate.

Guidance

BMBL

Bumble Sees Q2 Sales $235.000M-$243.000M vs $243.71M Est

Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $14.36, a high estimate of $29.00, and a low estimate of $7.00. A decline of 17.71% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1746655260_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Myriad Genetics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$7.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$10.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Dave Weiner</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.50</td>
<td>$11.50</td>
</tr>
<tr>
<td>Dave Weiner</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.50</td>
<td>$14.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$11.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>John Wilkin</td>
<td>Craig-Hallum</td>
<td>Announces</td>
<td>Buy</td>
<td>$29.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Myriad Genetics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Myriad Genetics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Myriad Genetics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MYGN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Myriad Genetics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Myriad Genetics: A Closer Look</h2>
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
<h3>Key Indicators: Myriad Genetics's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Myriad Genetics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.12% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Myriad Genetics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -20.18%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Myriad Genetics's ROE stands out, surpassing industry averages. With an impressive ROE of -5.93%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Myriad Genetics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -4.03%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.2.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MYGN

What Analysts Are Saying About Myriad Genetics Stock

In the preceding three months, 5 analysts have released ratings for Viridian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Viridian Therapeutics, presenting an average target of $36.0, a high estimate of $45.00, and a low estimate of $27.00. Highlighting a 5.76% decrease, the current average has fallen from the previous average price target of $38.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1746655250_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Viridian Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Richard Law</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$27.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$38.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$36.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Viridian Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Viridian Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Viridian Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Viridian Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VRDN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Viridian Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Viridian Therapeutics</h2>
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
<h3>Unraveling the Financial Story of Viridian Therapeutics</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Negative Revenue Trend: Examining Viridian Therapeutics's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately 0.0% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -110729.17%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -15.92%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -10.53%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Viridian Therapeutics's debt-to-equity ratio is below the industry average at 0.04, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRDN

What 5 Analyst Ratings Have To Say About Viridian Therapeutics

Ratings for Lear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEA#NYSE">LEA</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $99.9, a high estimate of $125.00, and a low estimate of $83.00. A 7.02% drop is evident in the current average compared to the previous average price target of $107.44. 
<img src="https://www.benzinga.com/files/images/story/2025/1746655230_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Lear among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Spak</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$89.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Michael Ward</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$123.00</td>
<td>-</td>
</tr>
<tr>
<td>Dan Levy</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$85.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Joseph Spak</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$83.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Mark Delaney</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$84.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Adam Jonas</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Chris McNally</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$110.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Joseph Spak</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$102.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$103.00</td>
<td>$99.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Lear. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Lear compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Lear's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Lear's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LEA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Lear analyst ratings.</a>
<h2>Delving into Lear's Background</h2>
Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns most of its revenue from the seating segment.
<h3>Breaking Down Lear's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Decline in Revenue: Over the 3M period, Lear faced challenges, resulting in a decline of approximately -2.17% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: Lear's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.54% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Lear's ROE excels beyond industry benchmarks, reaching 1.91%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Lear's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.61%, the company showcases efficient use of assets and strong financial health.
Debt Management: Lear's debt-to-equity ratio is below the industry average. With a ratio of 0.65, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Lear Stock

In the current session, the stock is trading at $622.93, after a 1.27% increase. Over the past month, argenx Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) stock increased by 10.42%, and in the past year, by 62.84%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1746655222_0.png" alt="Past Year Chart" />

<h3>argenx P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
argenx has a better P/E ratio of 48.13 than the aggregate P/E ratio of 47.71 of the Biotechnology industry. Ideally, one might believe that argenx Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1746655222_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

ARGX

A Look Into argenx Inc's Price Over Earnings

Throughout the last three months, 10 analysts have evaluated SanDisk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDK#NASDAQ">SNDK</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $61.9, with a high estimate of $84.00 and a low estimate of $39.00. Observing a downward trend, the current average is 4.28% lower than the prior average price target of $64.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1746655219_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive SanDisk. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Thomas O'Malley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$39.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Mehdi Hosseini</td>
<td>Susquehanna</td>
<td>Announces</td>
<td>Positive</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Matt Bryson</td>
<td>Wedbush</td>
<td>Announces</td>
<td>Outperform</td>
<td>$80.00</td>
<td>-</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Outperform</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Thomas O'Malley</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$50.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$84.00</td>
<td>-</td>
</tr>
<tr>
<td>Aaron Rakers</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$56.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to SanDisk. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of SanDisk compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of SanDisk's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of SanDisk's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SNDK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on SanDisk analyst ratings.</a>
<h2>Unveiling the Story Behind SanDisk</h2>
SanDisk Corp is one of the five largest suppliers of NAND flash memory semiconductors globally. Sandisk is vertically integrated, producing substantially all of its flash chips at manufacturing sites across Japan via a joint-venture framework with Kioxia. Sandisk then repackages majority of its chips into SSDs for consumer electronics, external storage, or cloud storage. Sandisk was formerly a piece of Western Digital for nine years (after being acquired in 2016) and was spun off as an independent company in 2025.
<h3>Key Indicators: SanDisk's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, SanDisk showcased positive performance, achieving a revenue growth rate of 12.67% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: SanDisk's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.54% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): SanDisk's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.87%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.73%, the company showcases effective utilization of assets.
Debt Management: SanDisk's debt-to-equity ratio is below the industry average at 0.06, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SNDK

What Analysts Are Saying About SanDisk Stock

Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) has outperformed the market over the past 5 years by 19.04% on an annualized basis producing an average annual return of 33.42%. Currently, Cloudflare has a market capitalization of $42.31 billion. 
Buying $1000 In NET: If an investor had bought $1000 of NET stock 5 years ago, it would be worth $4,328.24 today based on a price of $122.10 for NET at the time of writing.
<h3>Cloudflare's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746655215_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

MariMed (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. The company reported quarterly sales of $37.95 million which missed the analyst consensus estimate of $38.45 million by 1.29 percent. This is a 0.06 percent increase over sales of $37.93 million the same period last year.

Earnings Misses

MRMD

MariMed Q1 Adj. EPS $(0.01), Inline, Sales $37.95M Miss $38.45M Estimate

MISTRAS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MG#NYSE">MG</a>) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $0.13 by 107.69 percent. This is a 114.29 percent decrease over earnings of $0.07 per share from the same period last year. The company reported quarterly sales of $161.62 million which missed the analyst consensus estimate of $180.52 million by 10.47 percent. This is a 12.38 percent decrease over sales of $184.44 million the same period last year.

MISTRAS Group Q1 Adj. EPS $(0.01) Misses $0.13 Estimate, Sales $161.62M Miss $180.52M Estimate

WIIM

CVNA

CVNA stock has given up its prior loss. Carvana shares were trading lower. The company reported Q1 financial results.

Allied Gold (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AAUC#TSX">AAUC</a>) reported quarterly earnings of $0.14 per share. The company reported $346.41 million in sales this quarter. This is a 97.87 percent increase over sales of $175.07 million the same period last year.

TSX:AAUC

Allied Gold Q1 Adj. EPS $0.14, Sales $346.41M Up From $175.07M YoY

Cleveland-Cliffs Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) reported first-quarter financial results after the market close on Wednesday. Here&#8217;s a look at the key details from the <a href="https://www.benzinga.com/pressreleases/25/05/b45269632/cleveland-cliffs-reports-first-quarter-2025-results">steel producer&#8217;s report</a>.
Q1 Earnings: Cleveland-Cliffs reported first-quarter revenue of $4.63 billion, missing analyst <a href="http://benzinga.com/quote/clf/earnings">estimates</a> of $4.64 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The steelmaker reported a first-quarter adjusted loss of 92 cents per share, missing analyst estimates for a loss of 75 cents per share. 
Between March and May, the company decided to fully or partially idle six facilities to optimize its footprint, reposition away from loss-making operations and release excess working capital. These actions are expected to result in savings of over $300 million annually. 
&#8220;The decision to fully or partially idle certain locations was not taken lightly,&#8221; the company said. 
Total steelmaking revenues&nbsp;included&nbsp;$1.4 billion to the infrastructure and manufacturing market, $1.3 billion to the automotive market, $1.2 billion to the distributors and converters market and&nbsp;$588 million to steel producers.
Steel product sales volumes totaled 4.1 million net tons&nbsp;in the first quarter, consisting of 41%&nbsp;hot-rolled,&nbsp;27%&nbsp;coated,&nbsp;15%&nbsp;cold-rolled,&nbsp;5%&nbsp;plate,&nbsp;3%&nbsp;stainless and electrical and&nbsp;9%&nbsp;other.
Cleveland-Cliffs ended the quarter with $3 billion in total liquidity. 
&#8220;Our&nbsp;first-quarter&nbsp;results were negatively impacted by underperforming non-core assets and the lagging effect of lower index prices in late 2024 and early 2025,&#8221; said Lourenco Goncalves, chairman, president and CEO of Cleveland-Cliffs.
&#8220;As a result, we are taking decisive action to streamline our operations and enhance efficiency. This will drive meaningful fixed cost savings and sharpen our focus on our core strength: supplying steel to the automotive industry.&#8221;
Outlook: Cleveland-Cliffs expects full-year 2025 steel unit cost reductions of approximately&nbsp;$50&nbsp;per net ton compared to the prior year. The company anticipates full-year capital expenditures of approximately $625 million, down from prior guidance of $700 million. 
Cleveland-Cliffs executives will hold a conference call at 8:30 a.m. Thursday morning to further discuss the quarter with investors and analysts. 
CLF Price Action: <a href="http://benzinga.com/quote/clf">Cleveland-Cliffs shares</a> were down 9.19% after-hours, trading at $7.71 at the time of publication Wednesday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45268560/carvana-q1-earnings-revenue-eps-beat-estimates-as-vehicles-sales-jump-46-company-remains-on-track-for-significant-growth-in-fy25">Carvana Q1 Earnings: Revenue, EPS Beat Estimates As Vehicles Sales Jump 46%, Company Remains On Track For &#8216;Significant Growth&#8217; In FY25</a></li>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45268429/arm-holdings-stock-plunges-after-q4-results-heres-why">Arm Holdings Stock Plunges After Q4 Results: Here&#8217;s Why</a></li>
</ul>
Photo: saweang.w/Shutterstock.

Commodities

After-Hours Center

Cleveland-Cliffs Stock Falls On Q1 Earnings Miss, Steelmaker Idles 6 Facilities: 'Taking Decisive Action To Streamline Our Operations'

Schrodinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>) Software revenue growth is expected to range from 10% to 15%; Drug discovery revenue is expected to range from $45 million to $50 million.

SDGR

Schrodinger Software revenue growth is expected to range from 10% to 15%; Drug discovery revenue is expected to range from $45 million to $50 million.

Verisk Analytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) has outperformed the market over the past 15 years by 5.68% on an annualized basis producing an average annual return of 16.77%. Currently, Verisk Analytics has a market capitalization of $43.47 billion. 
Buying $100 In VRSK: If an investor had bought $100 of VRSK stock 15 years ago, it would be worth $1,035.76 today based on a price of $309.90 for VRSK at the time of writing.
<h3>Verisk Analytics's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746654312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRSK

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) affirms FY2025 sales outlook from $50.00 million-$53.00 million to $50.00 million-$53.00 million vs $61.78 million estimate.

Myomo Affirms FY2025 Sales Guidance of $50.00M-$53.00M vs $61.78M Est

Press Releases

STONECO LTD. ANNOUNCES EXPIRATION AND TENDER OFFER RESULTS

StoneCo Reports Second Quarter 2024 Results

Stone delivers a consistent quarter with strong TPV growth and advancements in credit and banking

Management

StoneCo Announces Additional Board Change

StoneCo Ltd. to Announce Third Quarter 2024 Financial Results on November 12th, 2024

StoneCo Reports Third Quarter 2024 Results

StoneCo. Announces New Share Repurchase Program of up to R$ 2 billion

StoneCo Ltd. to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 18th, 2025

StoneCo Reports Fourth Quarter and Fiscal Year 2024 Results

StoneCo Ltd. to Announce First Quarter 2025 Financial Results on May 08th, 2025

Affirm Holdings, Inc. - Class A Common Stock

Affirm Holdings

AvidXchange Holdings, Inc. - Common Stock

AvidXchange Holdings

Corpay

DLocal

Euronet Worldwide

Evertec

Fiserv

Fidelity National Information Services, Inc. Common Stock

Fidelity National Info

Shift4 Payments, Inc. Class A Common Stock

Shift4 Payments

Global Payments

Jack Henry & Associates, Inc. - Common Stock

Jack Henry & Associates

Mastercard

Marqeta

NCR Atleos

PagSeguro Digital Ltd. Class A Common Shares

PagSeguro Digital

Paymentus Holdings, Inc. Class A Common Stock

Paymentus Holdings

Payoneer Global

PayPal Holdings

Remitly Global

Sezzle

Toast

Visa

Western Union

Block

Barclays

Citigroup

Morgan Stanley

Goldman Sachs

JP Morgan

지난 일주일 동안 가장 실적이 좋았던 중형주 10개 종목은 다음과 같다.
<ol>
<li>디지넥스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>): 주가가 108.29% 급등했다. 이는 투자자 불확실성 및 여러 리스크 요인으로 인해 지난주 시장이 조정 국면에 들어간 후 전반적인 반등이 있었기 때문일 가능성이 높다.</li>
<li>넥스트데케이드 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXT#NASDAQ">NEXT</a>): 주가가 25.07% 상승했다. 미국 D.C. 항소법원이 2024년 8월 판결에 대한 수정을 발표하여 연방 에너지 규제 위원회의 명령에 대한 무효화 위험을 제거했다.</li>
<li>셀시우스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>): 주가가 21.60% 상승했다. 이는 펩시코(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>)가 프리바이오틱 <a href="https://www.benzinga.com//node/44360669" target="_blank" rel="noreferrer noopener">소다 브랜드 팝피(Poppi)를 19억 5천만 달러에 인수한다는 소식</a>에 반응했을 가능성이 높다.</li>
<li>시그넷 주얼러스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>): 주가가 21.08% 상승했다. 이는 2025회계연도 4분기 실적을 발표하고 여러 애널리스트가 <a href="https://www.benzinga.com//node/44423649" target="_blank" rel="noreferrer noopener">주가 전망을 수정한</a> 후 발생한 일이다.</li>
<li>뉴 포트리스 에너지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>): 주가가 20.63% 상승했다. 이는 달러 약세와 미국의 후티 공격 목표에 대한 공습으로 인한 영향, 그리고 강한 중국 경제 데이터가 수요 전망을 끌어올렸기 때문이다.</li>
<li>밀로즈 프로퍼티스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRP#NYSE">MRP</a>): 주가가 16.61% 상승했다. 이러한 급등은 회사가 첫 배당금을 선언하고 <a href="https://www.benzinga.com//node/44365712" target="_blank" rel="noreferrer noopener">2025년 전망을 발표</a>한 이후 발생했다.</li>
<li>아커티스 바이오테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>): 주가가 16.35% 상승했다. 이는 캐나다 보건부가 아토피성 피부염 치료를 위한 조리브(Zoryve) 크림을 승인한 후 발생한 일이다.</li>
<li>루시드 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>): 주가가 15.79% 상승했다. 이는 모건스탠리가 주식을 <a href="https://www.benzinga.com//node/44373086" target="_blank" rel="noreferrer noopener">비중축소에서 중립으로 상향 조정</a>한 이후 발생한 일이다.</li>
<li>캐털리스트 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>): 주가가 15.27% 상승했다.</li>
<li>스톤코 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>): 주가가 14.20% 상승했다. 이는 회사가 4분기 EPS 및 매출이 예상보다 좋게 나타났다고 발표한 후 나타났다.</li>
</ol>
사진 출처: Around the World Photos, Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

수요일 아침 (현지 시간 기준) 미국 주식 선물이 상승세를 보인 가운데, 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다:
<ul>
<li>월스트리트는 시그넷 주얼러스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>)가 분기 실적을 주당 6.25달러, 매출을 23억 3천만 달러로 발표할 것으로 예상하고 있다. <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>의 데이터에 따르면, 시그넷의 주식은 시간외 거래에서 0.3% 상승한 48.42달러에 거래되었다.</li>
<li>애널리스트들은 윌리엄스-소노마(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>)가 분기 실적을 주당 2.93달러, 매출을 23억 5천만 달러로 발표할 것으로 예상하고 있다. 이 회사는 개장 전에 실적을 발표할 예정이다. 윌리엄스-소노마의 주식은 화요일에 1.6% 하락하여 172.28달러에 거래를 마쳤다.</li>
<li>헬스에퀴티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>)는 화요일에 4분기 실적이 부진하다고 발표했다. 헬스에퀴티는 2026 회계연도 매출을 12억 8천만 달러에서 13억 5천만 달러로 예상하며, 이는 13억 1천만 달러에 대한 예상치와 일치한다. 이 회사는 연간 실적을 주당 3.57달러에서 3.74달러로 예상하며, 이는 주당 3.71달러에 대한 예상치와 일치합니다. 헬스에퀴티의 주식은 시간외 거래에서 13.7% 하락하여 87.75달러에 거래되었다.</li>
</ul>
자세한 내용은 <a href="https://www.benzinga.com/premarket/">여기에서 사전 시장 보도를 확인하세요</a>
<ul>
<li>스톤코(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>)는 4분기 실적과 매출이 예상보다 좋았다고 보고했다. 스톤코의 주식은 시간외 거래에서 10.2% 상승하여 10.85달러에 거래되었다.</li>
<li>애널리스트들은 파이브 빌로우(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>)가 분기 실적을 주당 3.38달러, 매출을 13억 9천만 달러로 발표할 것으로 예상하고 있다. 파이브 빌로우의 주식은 시간 외 거래에서 1.3% 상승하여 74.88달러에 거래되었다.</li>
</ul>
이것도 확인해보세요: <a href="https://www.benzinga.com/25/03/44375233/top-3-materials-stocks-which-could-rescue-your-portfolio-this-month">이달에 포트폴리오를 구해줄 수 있는 상위 3개 소재 주식</a>
사진 제공: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

CNN 머니 공포·탐욕 지수는 전체 시장 정서에서 약간의 개선을 보여주었지만, 월요일에도 여전히 &#8220;극단적 공포&#8221; 영역에 머물렀다.
미국 주식은 월요일(17일)에 상승세를 보였으며, 다우존스 지수가 거래 중에 350포인트 이상 급등했다. 주요 지수 3개 모두 연속으로 상승했다.
월요일에 상승세를 나타냈음에도 불구하고, 미국 주식은 지난주 하락을 기록했다. 다우 지수는 약 3.1% 하락하여 2023년 3월 이후 최악의 주간 실적을 기록했고, S&amp;P 500은 2% 이상 하락하여 4주 연속 하락세를 나타냈다.
게스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) 주가는 회사가 WHP 글로벌로부터 주당 13달러 현금으로 회사를 인수하겠다는 비구속적 제안을 받았다고 발표한 후 월요일에 30% 급등했다. 바이두(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) 주가는 &#8216;어니 4.5&#8217; 및 딥씽킹 모델 &#8216;어니 X1&#8217;의 출시를 발표한 후 9% 상승했다.
경제지표 측면에서, 미국 소매판매는 2월에 전월 대비 0.2% 증가했으며, 시장 예상치 0.6% 상승에는 미치지 못했다. 단, 1월 소매판매는 1.2% 감소로 하향 수정되었다. NY 엠파이어 스테이트 제조업 지수는 3월에 26포인트 하락한 -20.0을 기록하며 2023년 5월 이후 최저치를 기록했다. NAHB/웰스파고 주택시장 지수는 3월에 39로 하락했으며, 2월에는 42를 기록했다.
S&amp;P 500 지수 대부분의 섹터는 월요일에 상승세를 보였고 특히 부동산, 에너지 및 필수소비재 섹터가 가장 큰 상승폭을 기록했다. 하지만 임의소비재 섹터는 시장 추세와 반대로 하락했다.
투자자들은 IHS 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>), 헬스에퀴티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>), 스톤코(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) 등의 실적 발표를 기다리고 있다.
다우존스는 월요일에 약 353포인트 상승하여 41,841.63포인트로 마감했다. S&amp;P 500은 0.64% 상승하여 5,675.12포인트로 상승했고, 나스닥 종합 지수는 월요일 거래 중 0.31% 상승하여 17,808.66포인트로 마감했다.
<h3>CNN 비즈니스 공포·탐욕 지수란?</h3>
공포·탐욕 지수는 현재 22.1로, 월요일에 &#8220;극단적 공포&#8221; 영역에 머물렀다. 이전 지수는 20.9였다.
공포·탐욕 지수는 현재 시장 심리를 측정하는 지표다. 공포가 높을수록 주가에 압력을 가하고, 탐욕이 높을수록 주가를 상승시킨다는 전제를 바탕으로 한다. 이 지수는 동일한 가중치를 가진 7가지 지표를 기준으로 계산된다. 지수의 범위는 0에서 100까지이며 0은 최대 공포를, 100은 최대 탐욕을 나타낸다.
사진 제공: Shutterstock

긍정적 경제지표로 다우 지수 350p 상승: 투자자 불안 완화, 탐욕 지수는 '극단적 공포' 영역

화요일(18일) 미국 지수 선물이 하락세를 보이고 있는 가운데, 오늘 투자자의 주목을 받을 수 있는 주식은 다음과 같다.
<ul>
<li>IHS 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>): 화요일 개장 전 실적을 발표할 예정이며, 월가에서는 주당순이익 4센트, 매출 4억 2,400만 달러를 예상하고 있다. 주식은 월요일 애프터마켓에서 0.5% 상승하여 3.93달러에 거래되었다.</li>
<li>헬스에퀴티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>): 화요일 장 마감 후 실적을 발표할 예정이며, 주당순이익 72센트와 매출 3억 6,605만 달러를 발표할 것으로 예상된다. 주식은 월요일 애프터마켓에서 1.1% 상승하여 101.87달러에 거래되었다.</li>
<li>게티 이미지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>): 월요일에 4분기 긍정적인 실적을 발표했다. 주식은 월요일 애프터마켓에서 0.9% 하락하여 2.1301달러에 거래되었다.</li>
</ul>
자세한 내용은 <a href="https://www.benzinga.com/premarket/" target="_blank" rel="noopener">프리마켓 보도</a>를 확인하세요.
<ul>
<li>상가모 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>): 예상보다 저조한 4분기 재무 실적을 발표했다. 주식은 월요일 애프터마켓에서 3% 하락하여 0.98달러에 거래되었다.</li>
<li>스톤코(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>): 장 마감 후 실적을 발표할 예정이며, 분기 주당순이익 35센트와 매출 6억 4,756만 달러를 발표할 것으로 예상한다. 주식은 월요일 애프터마켓에서 0.1% 상승하여 10.20달러에 거래되었다.</li>
</ul>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

SGMO

화요일 주목해야 할 주식: IHS 홀딩, 헬스에퀴티, 게티 이미지, 상가모 테라퓨틱스 및 스톤코

리스크 온(Risk-on) 심리가 추수감사절 이후 월스트리트에서 힘을 얻으면서, 미국 기업들의 4분기 이익 전망에 대한 투자자들의 낙관론으로 S&amp;P 500과 다우지수가 모두 새로운 <a href="https://www.benzinga.com/markets" target="_blank" rel="noopener" data-google-interstitial="false">기록 최고치를 경신</a>했다.
S&amp;P 500 지수는 금요일에 6,040포인트를 돌파하고 6,032로 마감하여 연초 대비 27%라는 인상적인 상승률을 기록했다. 만약 금요일에 연도가 끝났다면, 미국 주식 시장은 지난 2년 동안 무려 57%나 급등했을 것이며, 이는 1998년 이후 가장 강력한 상승세이다.
다우지수도 45,000포인트를 넘어서는 기록을 세웠고, 연초 대비 19% 상승했다.
기술주들이 선전하며, 나스닥 100 지수가 이날 1% 상승했다. 이는 &#8216;매그니피센트 세븐&#8217; 메가캡 주식들과 반도체 주식들의 상승으로 인해 발생한 일이다.
소형주들은 더 완만한 상승세를 보였으며, 러셀 2000 지수는 0.4% 상승했다.
환율 시장에서는 일본 엔에 대한 약세로로 인해 미국 달러가 8주 연속 상승세를 끊고 주간 하락을 기록했다. 이는 일본은행의 금리 인상 가능성에 대한 추측 때문이다.
채권 시장에서는 국채 수익률이 약 5베이시스포인트(bp) 하락했으며, 10년물 수익률은 4.2%에 가까워졌다. 이는 10월 말 이후로 보지 못한 수준이다. iShares 20년 이상 국채 ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>)는 1% 상승하여 한 달 이상 만에 최고치를 기록했다.
원자재 시장에서도 긍정적인 가격 움직임이 있었다. 금은 0.8% 상승하여 4일 연속 상승세를 이어갔고, 은은 1.4% 급등했다. 천연가스 가격은 4.9% 급등하여 월간 상승률이 24%에 달했다. 반면, 원유는 0.2% 하락했다.
암호화폐 시장에서는 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)가 1.6% 반등하여 $97,000를 넘어섰고, 이는 디지털 자산 그룹이 더 넓은 시장의 열광 속에서도 회복력을 보이고 있음을 나타낸다.
<h3 class="wp-block-heading">금요일 주요 미국 지수 및 ETF 성과</h3>
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>주요 지수</td>
<td>가격</td>
<td>변동률 (%)</td>
</tr>
<tr>
<td>나스닥 100</td>
<td>20,930</td>
<td>+0.9%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,032</td>
<td>+0.6%</td>
</tr>
<tr>
<td>다우지수</td>
<td>44,910</td>
<td>+0.4%</td>
</tr>
<tr>
<td>러셀 2000</td>
<td>2,434</td>
<td colspan="2">+0.3%</td>
</tr>
</tbody>
</table><figcaption class="wp-element-caption">오후 1시에 업데이트됨. ET</figcaption></figure>
다음은 <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1">벤징가 프로</a> 데이터에 따른 정보이다:
<ul>
<li>SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)는 0.6% 상승하여 $509.61로 마감했다.</li>
<li>SPDR 다우 존스 산업평균지수(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)는 0.5% 상승하여 $450로 마감했다.</li>
<li>기술주 중심의 Invesco QQQ Trust Series(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)는 0.9% 상승하여 $509.61로 마감했다.</li>
<li>iShares 러셀 2000 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>)는 0.5% 상승하여 $242.10로 마감했다.</li>
<li>Technology Select Sector SPDR Fund(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)는 0.9% 상승하여 주목을 받았고, Real Estate Select Sector SPDR Fund(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)는 0.5% 하락하여 부진한 성적을 기록했다.</li>
</ul>
금요일 주식 움직임:
<ul>
<li>애플(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)는 주당 $273.62로 1.1% 상승하며 새로운 최고가를 기록다.</li>
<li>룰라 정부의 최근 재정 개혁에 투자자들이 실망하면서 미국 상장 브라질 기업의 주식이 크게 매도됐다. 누 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NU#NASDAQ">NU</a>), 스톤코(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) 및 XP(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XP#NASDAQ">XP</a>)의 주가는 각각 7.2%, 9.1%, 9.2% 하락했다.</li>
<li>테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)는 웨드부시가 이 전기차(EV) 거대 기업이 인공지능(AI) 및 자율 주행 기회에서 $1조를 활용할 수 있을 것으로 예상한 후 4% 상승했으며, 규제 장애물이 줄어들어 잠재적으로 가치가 $1.5조에서 $2조로 높아질 수 있다.</li>
</ul>
다음 읽어볼 내용:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42247850/gm-other-us-automakers-brace-for-sharp-profit-squeeze-from-trump-tariffs-analysts-warn">GM 및 기타 미국 자동차 제조사, 트럼프 관세로 인한 급격한 이익 압박 경고</a></li>
</ul>
Photo via Shutterstock.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Cryptocurrency

Large Cap

Broad U.S. Equity ETFs

Forex

ETFs

$BTC

AAPL

TSLA

XLRE

S&P 500, 다우지수 사상 최고치 경신; 달러 8주 상승 후 하락; 비트코인 $97,000 돌파

수요일에 캐시 우드의 아크 인베스트(Ark Invest)는 몇 가지 중요한 거래를 했다. 그 중 가장 눈에 띄는 것은 쇼피파이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>), 레딧(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>)의 주식 매수, 그리고 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)의 주식 매각이다.
쇼피파이 거래:
아크 인베스트의 Ark Fintech Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>), ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>), 그리고 ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)은 쇼피파이의 총 482,042주를 매입했다. 이 거래의 가치는 3,024만 달러에 달했다. 이날 쇼피파이의 주가는 정규 거래에서 18.59% 하락한 62.73달러에 마감했다.
이러한 움직임은 이 회사가 분기별 실적을 보고한 후 주가가 급락했음에도 불구하고 이루어졌다. <a href="https://www.benzinga.com/news/earnings/24/05/38703997/shopify-stock-plunges-after-q1-print-as-sale-of-logistics-business-weigh">벤징가(Benzinga) 보고서</a>에 따르면 쇼피파이의 매출은 전년 동기 대비 23% 증가한 18억 6천만 달러로 합의 추정치인 18억 4,500만 달러를 넘어섰다. 그러나 이 회사는 1년 전 6,800만 달러의 이익을 낸 후 2억 7,300만 달러의 손실을 보고했다.
레딧 거래:
아크 인베스트의 ETF인 ARKF와 ARKW는 레딧의 주식을 총 115,394주에 593만 달러에 매입했다. 수요일 레딧의 주식은 4.05% 상승하여 51.40달러에 마쳤다.
이 소셜 미디어 플랫폼의 주가는 <a href="https://www.benzinga.com/news/earnings/24/05/38683061/reddit-shares-soar-on-first-post-ipo-q1-results-strong-q2-guidance" target="_blank" rel="noopener">1분기 재무 결과</a>를 보고하고 2분기에 강력한 지침을 제시한 직후 급등했다. 레딧의 분기별 매출은 2억 4,296만 3천 달러로 분석가의 합의 추정치인 2억 1,283만 달러를 14.16% 앞섰다.
코인베이스 거래:
아크 인베스트의 ETF인 ARKF와 ARKW는 코인베이스 글로벌의 주식 총 41,964주를 매입했다. 주식을 사들인 금액은 889만 달러였다. 이날 코인베이스의 주식은 1.46% 하락하여 211.20달러에 마쳤다.
<a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38720330/bitcoin-ethereum-dogecoin-continue-to-slip-analyst-says-king-crypto-network-fundamentals-i" target="_blank" rel="noopener">Benzinga</a>의 보고에 따르면 아크의 움직임은 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)의 ​​가격이 하락하는 가운데 이루어졌다. 코인베이스 주가는 수요일 1.46% 하락한 211.2달러로 마감됐다.
다른 중요한 거래들:
<ul>
<li>아크 인베스트의 ARKF는 글로벌-e 온라인(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>)의 주를 팔았다. ARKF는 또한 트윌리오(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NASDAQ">TWLO</a>)와 스톤코코(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>)의 주도 각각 팔았다.</li>
<li>ARKK는 드래프트킹스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>)의 주도 팔았으며 트위스트 바이오사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>)의 주도 팔았다. ARKQ는 에어로바이런먼트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>)와 2U(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>)의 주를 팔았지만, 로켓 랩 USA(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>)의 주는 매입했다.</li>
</ul>
<div style="font-family: 'Lato', sans-serif;">
<hr style="border: 0; height: 5px; background: #225aa9;" />
<div style="background-color: #f5f5f5; background-position: center; background-size: cover; justify-content: center;"></div>
이 콘텐츠는 Benzinga Neuro가 제작하였고, <a style="color: #225aa9; text-decoration: none;" href="None" target="_blank" rel="noopener">Shivdeep Dhaliwal</a>이 편집했습니다. 
<hr style="border: 0; height: 1px; background: #225aa9;" />
GPT-4 기반 Benzinga Neuro 콘텐츠 생성 시스템은 네이티브 데이터, API 등을 활용하여 포괄적이고 시급한 이야기를 만들어냅니다. 
<a style="color: #225aa9; text-decoration: none;" href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener">더 알아보기.</a>
<hr style="border: 0; height: 5px; background: #225aa9;" />
</div>

ARKF

ARKK

ARKW

AVAV

COIN

DKNG

GLBE

RDDT

RKLB

SHOP

TWLO

TWOU

TWST

아크 인베스트는 쇼피파이 주식 $3,000만 이상 매입, 레딧도 매수, 코인베이스 주식은 매도

화요일, 캐시 우드의 아크 인베스트는 전기차 업체인 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)의 주식이 부진한 분기 실적으로 약세임에도 불구하고 계속해서 적극적으로 매입했다.
테슬라 거래
아크 인베스트는 ARK 혁신 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>), ARK 자율 기술 및 로보틱스 ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>), ARK 차세대 인터넷 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>) 를 통해 테슬라의 주식 29,230주를 매입했다. 이번 매입은 <a href="https://www.benzinga.com/news/earnings/24/04/38390883/tesla-q1-earnings-highlights-ev-giant-misses-wall-street-estimates-makes-cost-cuts-invests-in-ai-sp">테슬라의 1분기 실적 발표</a> 이후 진행되었는데, 이 실적 발표에서는 전년도 동기대비 매출이 9% 감소한 결과가 나와 월스트리트의 컨센서스 추정치에 미달했다.
이번 매입은, 화요일 144.68달러의 주식 종가를 기준으로, 아크 인베스트가 매입한 테슬라 주식의 가치는 약 430만달러에 이른다. 이번 결정은 테슬라의 1분기 실적 발표를 앞둔 전날 <a href="https://www.benzinga.com/markets/equities/24/04/38368840/cathie-woods-ark-invest-seizes-tesla-dip-acquires-over-17m-in-shares-ahead-of-q1-results-zoom-st">17백만 달러 이상의 테슬라 주식을 매수</a>에 이은 것이다.
기타 중요한 거래들:
다음 읽기: <a href="https://www.benzinga.com/news/24/04/38347033/bound-by-courtroom-rules-donald-trump-is-doing-something-uncommon-for-his-public-persona-staying-sil?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">법정 규칙에 얽매인 트럼프는 공개적인 인물로서 흔치 않은 행동을 하고 있다: 침묵을 유지하는 것</a>
<ul>
<li>Ark 핀텍 혁신 ETF(ARKF)는 스톤코(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) 의 주식을 팔았다.</li>
<li>ARKF는 트윌리오(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NASDAQ">TWLO</a>)의 1,205주도 처분했다. ARKK와 ARKQ는 각각 2U Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>)의 상당수 주식을 팔았다.</li>
<li>ARKW도 트윌리오와 2U Inc 주식을 소규모로 팔았다.</li>
</ul>

<div style="font-family: 'Lato', sans-serif;">
<hr style="border: 0; height: 5px; background: #225aa9;" />
<div style="background-color: #f5f5f5; background-position: center; background-size: cover; justify-content: center;"></div>
<hr style="border: 0; height: 1px; background: #225aa9;" />
<hr style="border: 0; height: 5px; background: #225aa9;" />
</div>

Comments

StoneCo

뉴스

에 대한 최신 뉴스 StoneCo (NASDAQ:STNE) 주식

일요일, 3월 23, 2025

수요일, 3월 19, 2025

화요일, 3월 18, 2025

금요일, 11월 29, 2024

목요일, 5월 09, 2024

수요일, 4월 24, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌